Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme
Therapy options at the time of recurrence of glioblastoma multiforme are often limited. We investigated whether treatment with a new intratumoral thermotherapy procedure using magnetic nanoparticles improves survival outcome. In a single-arm study in two centers, 66 patients (59 with recurrent gliob...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 2011-06, Vol.103 (2), p.317-324 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 324 |
|---|---|
| container_issue | 2 |
| container_start_page | 317 |
| container_title | Journal of neuro-oncology |
| container_volume | 103 |
| creator | Maier-Hauff, Klaus Ulrich, Frank Nestler, Dirk Niehoff, Hendrik Wust, Peter Thiesen, Burghard Orawa, Helmut Budach, Volker Jordan, Andreas |
| description | Therapy options at the time of recurrence of glioblastoma multiforme are often limited. We investigated whether treatment with a new intratumoral thermotherapy procedure using magnetic nanoparticles improves survival outcome. In a single-arm study in two centers, 66 patients (59 with recurrent glioblastoma) received neuronavigationally controlled intratumoral instillation of an aqueous dispersion of iron-oxide (magnetite) nanoparticles and subsequent heating of the particles in an alternating magnetic field. Treatment was combined with fractionated stereotactic radiotherapy. A median dose of 30 Gy using a fractionation of 5 × 2 Gy/week was applied. The primary study endpoint was overall survival following diagnosis of first tumor recurrence (OS-2), while the secondary endpoint was overall survival after primary tumor diagnosis (OS-1). Survival times were calculated using the Kaplan–Meier method. Analyses were by intention to treat. The median overall survival from diagnosis of the first tumor recurrence among the 59 patients with recurrent glioblastoma was 13.4 months (95% CI: 10.6–16.2 months). Median OS-1 was 23.2 months while the median time interval between primary diagnosis and first tumor recurrence was 8.0 months. Only tumor volume at study entry was significantly correlated with ensuing survival (
P
|
| doi_str_mv | 10.1007/s11060-010-0389-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3097345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>876226980</sourcerecordid><originalsourceid>FETCH-LOGICAL-c548t-7092a2cbd1dc93543dce1277a37cce1307953e9463d7ff4e13d607f63cb36c2f3</originalsourceid><addsrcrecordid>eNp1kk2P1SAUhonRONerP8CNIW5cVaG00G5MzGT8SCZxo4k7Qumhl0mBK1Cd-8P8f9J0vH4kLvg65z0PcPIi9JSSl5QQ8SpRSjipCC2DdX1F7qEdbQWrBBPsPtoRykXV9s2XC_QopRtCSCMYfYguatI1LeF0h35cGWO10ies_IiTMpBPOBhsfY4qLy5ENeN8gOjCOqvjCS_J-gk7NXnIVmMbg6_CrR0Be-XDUcUSnSFhHdxgPYz4u80HDLcZoi-wAZTDUY32DAweH1W24HPatBH0EmM542m2YZhVysEp7JY5WxOig8fogVFzgid36x59fnv16fJ9df3x3YfLN9eVbpsuV4L0tar1MNJR96xt2KiB1kIoJnTZMSL6lkHfcDYKY5oSGTkRhjM9MK5rw_bo9cY9LoODUr12ZZbHaJ2KJxmUlX9nvD3IKXyTjPSCNW0BvLgDxPB1gZSls0nDPCsPYUmyE7yued-Ronz-j_ImLGvDioiLpqeiEPeIbiIdQ0oRzPkplMjVEnKzhCyWkKsl5Ap-9ucfzhW_PFAE9SZIJeUniL9v_j_1JwivyMw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>867491797</pqid></control><display><type>article</type><title>Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Maier-Hauff, Klaus ; Ulrich, Frank ; Nestler, Dirk ; Niehoff, Hendrik ; Wust, Peter ; Thiesen, Burghard ; Orawa, Helmut ; Budach, Volker ; Jordan, Andreas</creator><creatorcontrib>Maier-Hauff, Klaus ; Ulrich, Frank ; Nestler, Dirk ; Niehoff, Hendrik ; Wust, Peter ; Thiesen, Burghard ; Orawa, Helmut ; Budach, Volker ; Jordan, Andreas</creatorcontrib><description>Therapy options at the time of recurrence of glioblastoma multiforme are often limited. We investigated whether treatment with a new intratumoral thermotherapy procedure using magnetic nanoparticles improves survival outcome. In a single-arm study in two centers, 66 patients (59 with recurrent glioblastoma) received neuronavigationally controlled intratumoral instillation of an aqueous dispersion of iron-oxide (magnetite) nanoparticles and subsequent heating of the particles in an alternating magnetic field. Treatment was combined with fractionated stereotactic radiotherapy. A median dose of 30 Gy using a fractionation of 5 × 2 Gy/week was applied. The primary study endpoint was overall survival following diagnosis of first tumor recurrence (OS-2), while the secondary endpoint was overall survival after primary tumor diagnosis (OS-1). Survival times were calculated using the Kaplan–Meier method. Analyses were by intention to treat. The median overall survival from diagnosis of the first tumor recurrence among the 59 patients with recurrent glioblastoma was 13.4 months (95% CI: 10.6–16.2 months). Median OS-1 was 23.2 months while the median time interval between primary diagnosis and first tumor recurrence was 8.0 months. Only tumor volume at study entry was significantly correlated with ensuing survival (
P
< 0.01). No other variables predicting longer survival could be determined. The side effects of the new therapeutic approach were moderate, and no serious complications were observed. Thermotherapy using magnetic nanoparticles in conjunction with a reduced radiation dose is safe and effective and leads to longer OS-2 compared to conventional therapies in the treatment of recurrent glioblastoma.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-010-0389-0</identifier><identifier>PMID: 20845061</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Brain Neoplasms - mortality ; Brain Neoplasms - therapy ; Clinical Study – Patient Study ; Combined Modality Therapy ; Dose Fractionation ; Ferric Compounds - administration & dosage ; Glioblastoma - mortality ; Glioblastoma - therapy ; Humans ; Hyperthermia, Induced - methods ; Kaplan-Meier Estimate ; Magnetics ; Medicine ; Medicine & Public Health ; Middle Aged ; Nanoparticles - administration & dosage ; Neoplasm Recurrence, Local - therapy ; Neurology ; Neuronavigation ; Oncology</subject><ispartof>Journal of neuro-oncology, 2011-06, Vol.103 (2), p.317-324</ispartof><rights>The Author(s) 2010</rights><rights>Springer Science+Business Media, LLC. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c548t-7092a2cbd1dc93543dce1277a37cce1307953e9463d7ff4e13d607f63cb36c2f3</citedby><cites>FETCH-LOGICAL-c548t-7092a2cbd1dc93543dce1277a37cce1307953e9463d7ff4e13d607f63cb36c2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-010-0389-0$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-010-0389-0$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20845061$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maier-Hauff, Klaus</creatorcontrib><creatorcontrib>Ulrich, Frank</creatorcontrib><creatorcontrib>Nestler, Dirk</creatorcontrib><creatorcontrib>Niehoff, Hendrik</creatorcontrib><creatorcontrib>Wust, Peter</creatorcontrib><creatorcontrib>Thiesen, Burghard</creatorcontrib><creatorcontrib>Orawa, Helmut</creatorcontrib><creatorcontrib>Budach, Volker</creatorcontrib><creatorcontrib>Jordan, Andreas</creatorcontrib><title>Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Therapy options at the time of recurrence of glioblastoma multiforme are often limited. We investigated whether treatment with a new intratumoral thermotherapy procedure using magnetic nanoparticles improves survival outcome. In a single-arm study in two centers, 66 patients (59 with recurrent glioblastoma) received neuronavigationally controlled intratumoral instillation of an aqueous dispersion of iron-oxide (magnetite) nanoparticles and subsequent heating of the particles in an alternating magnetic field. Treatment was combined with fractionated stereotactic radiotherapy. A median dose of 30 Gy using a fractionation of 5 × 2 Gy/week was applied. The primary study endpoint was overall survival following diagnosis of first tumor recurrence (OS-2), while the secondary endpoint was overall survival after primary tumor diagnosis (OS-1). Survival times were calculated using the Kaplan–Meier method. Analyses were by intention to treat. The median overall survival from diagnosis of the first tumor recurrence among the 59 patients with recurrent glioblastoma was 13.4 months (95% CI: 10.6–16.2 months). Median OS-1 was 23.2 months while the median time interval between primary diagnosis and first tumor recurrence was 8.0 months. Only tumor volume at study entry was significantly correlated with ensuing survival (
P
< 0.01). No other variables predicting longer survival could be determined. The side effects of the new therapeutic approach were moderate, and no serious complications were observed. Thermotherapy using magnetic nanoparticles in conjunction with a reduced radiation dose is safe and effective and leads to longer OS-2 compared to conventional therapies in the treatment of recurrent glioblastoma.</description><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - therapy</subject><subject>Clinical Study – Patient Study</subject><subject>Combined Modality Therapy</subject><subject>Dose Fractionation</subject><subject>Ferric Compounds - administration & dosage</subject><subject>Glioblastoma - mortality</subject><subject>Glioblastoma - therapy</subject><subject>Humans</subject><subject>Hyperthermia, Induced - methods</subject><subject>Kaplan-Meier Estimate</subject><subject>Magnetics</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nanoparticles - administration & dosage</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Neurology</subject><subject>Neuronavigation</subject><subject>Oncology</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kk2P1SAUhonRONerP8CNIW5cVaG00G5MzGT8SCZxo4k7Qumhl0mBK1Cd-8P8f9J0vH4kLvg65z0PcPIi9JSSl5QQ8SpRSjipCC2DdX1F7qEdbQWrBBPsPtoRykXV9s2XC_QopRtCSCMYfYguatI1LeF0h35cGWO10ies_IiTMpBPOBhsfY4qLy5ENeN8gOjCOqvjCS_J-gk7NXnIVmMbg6_CrR0Be-XDUcUSnSFhHdxgPYz4u80HDLcZoi-wAZTDUY32DAweH1W24HPatBH0EmM542m2YZhVysEp7JY5WxOig8fogVFzgid36x59fnv16fJ9df3x3YfLN9eVbpsuV4L0tar1MNJR96xt2KiB1kIoJnTZMSL6lkHfcDYKY5oSGTkRhjM9MK5rw_bo9cY9LoODUr12ZZbHaJ2KJxmUlX9nvD3IKXyTjPSCNW0BvLgDxPB1gZSls0nDPCsPYUmyE7yued-Ronz-j_ImLGvDioiLpqeiEPeIbiIdQ0oRzPkplMjVEnKzhCyWkKsl5Ap-9ucfzhW_PFAE9SZIJeUniL9v_j_1JwivyMw</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Maier-Hauff, Klaus</creator><creator>Ulrich, Frank</creator><creator>Nestler, Dirk</creator><creator>Niehoff, Hendrik</creator><creator>Wust, Peter</creator><creator>Thiesen, Burghard</creator><creator>Orawa, Helmut</creator><creator>Budach, Volker</creator><creator>Jordan, Andreas</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20110601</creationdate><title>Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme</title><author>Maier-Hauff, Klaus ; Ulrich, Frank ; Nestler, Dirk ; Niehoff, Hendrik ; Wust, Peter ; Thiesen, Burghard ; Orawa, Helmut ; Budach, Volker ; Jordan, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c548t-7092a2cbd1dc93543dce1277a37cce1307953e9463d7ff4e13d607f63cb36c2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - therapy</topic><topic>Clinical Study – Patient Study</topic><topic>Combined Modality Therapy</topic><topic>Dose Fractionation</topic><topic>Ferric Compounds - administration & dosage</topic><topic>Glioblastoma - mortality</topic><topic>Glioblastoma - therapy</topic><topic>Humans</topic><topic>Hyperthermia, Induced - methods</topic><topic>Kaplan-Meier Estimate</topic><topic>Magnetics</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nanoparticles - administration & dosage</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Neurology</topic><topic>Neuronavigation</topic><topic>Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maier-Hauff, Klaus</creatorcontrib><creatorcontrib>Ulrich, Frank</creatorcontrib><creatorcontrib>Nestler, Dirk</creatorcontrib><creatorcontrib>Niehoff, Hendrik</creatorcontrib><creatorcontrib>Wust, Peter</creatorcontrib><creatorcontrib>Thiesen, Burghard</creatorcontrib><creatorcontrib>Orawa, Helmut</creatorcontrib><creatorcontrib>Budach, Volker</creatorcontrib><creatorcontrib>Jordan, Andreas</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maier-Hauff, Klaus</au><au>Ulrich, Frank</au><au>Nestler, Dirk</au><au>Niehoff, Hendrik</au><au>Wust, Peter</au><au>Thiesen, Burghard</au><au>Orawa, Helmut</au><au>Budach, Volker</au><au>Jordan, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>103</volume><issue>2</issue><spage>317</spage><epage>324</epage><pages>317-324</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Therapy options at the time of recurrence of glioblastoma multiforme are often limited. We investigated whether treatment with a new intratumoral thermotherapy procedure using magnetic nanoparticles improves survival outcome. In a single-arm study in two centers, 66 patients (59 with recurrent glioblastoma) received neuronavigationally controlled intratumoral instillation of an aqueous dispersion of iron-oxide (magnetite) nanoparticles and subsequent heating of the particles in an alternating magnetic field. Treatment was combined with fractionated stereotactic radiotherapy. A median dose of 30 Gy using a fractionation of 5 × 2 Gy/week was applied. The primary study endpoint was overall survival following diagnosis of first tumor recurrence (OS-2), while the secondary endpoint was overall survival after primary tumor diagnosis (OS-1). Survival times were calculated using the Kaplan–Meier method. Analyses were by intention to treat. The median overall survival from diagnosis of the first tumor recurrence among the 59 patients with recurrent glioblastoma was 13.4 months (95% CI: 10.6–16.2 months). Median OS-1 was 23.2 months while the median time interval between primary diagnosis and first tumor recurrence was 8.0 months. Only tumor volume at study entry was significantly correlated with ensuing survival (
P
< 0.01). No other variables predicting longer survival could be determined. The side effects of the new therapeutic approach were moderate, and no serious complications were observed. Thermotherapy using magnetic nanoparticles in conjunction with a reduced radiation dose is safe and effective and leads to longer OS-2 compared to conventional therapies in the treatment of recurrent glioblastoma.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>20845061</pmid><doi>10.1007/s11060-010-0389-0</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2011-06, Vol.103 (2), p.317-324 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3097345 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Brain Neoplasms - mortality Brain Neoplasms - therapy Clinical Study – Patient Study Combined Modality Therapy Dose Fractionation Ferric Compounds - administration & dosage Glioblastoma - mortality Glioblastoma - therapy Humans Hyperthermia, Induced - methods Kaplan-Meier Estimate Magnetics Medicine Medicine & Public Health Middle Aged Nanoparticles - administration & dosage Neoplasm Recurrence, Local - therapy Neurology Neuronavigation Oncology |
| title | Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20intratumoral%20thermotherapy%20using%20magnetic%20iron-oxide%20nanoparticles%20combined%20with%20external%20beam%20radiotherapy%20on%20patients%20with%20recurrent%20glioblastoma%20multiforme&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Maier-Hauff,%20Klaus&rft.date=2011-06-01&rft.volume=103&rft.issue=2&rft.spage=317&rft.epage=324&rft.pages=317-324&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-010-0389-0&rft_dat=%3Cproquest_pubme%3E876226980%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=867491797&rft_id=info:pmid/20845061&rfr_iscdi=true |